Management of Severe Anemia

Initial Assessment and Management

For a patient with severe anemia, red blood cell transfusion is indicated to rapidly increase oxygen-carrying capacity and prevent tissue hypoxia, as recommended by the American Association for the Study of Liver Diseases and the Society of Critical Care Medicine 1, 2
Severe anemia with hemoglobin 6 g/dL requires immediate intervention as this level is below the critical threshold of 7 g/dL, which compromises adequate oxygen delivery to tissues, according to the American Association for the Study of Liver Diseases 1
Red blood cell transfusion is the first-line treatment when hemoglobin falls below 7 g/dL to rapidly restore oxygen-carrying capacity, as stated by the National Comprehensive Cancer Network and the Society of Critical Care Medicine 1, 2, 3
The goal of transfusion should be to increase hemoglobin to 7-9 g/dL, following a restrictive transfusion strategy, as recommended by the American Association for the Study of Liver Diseases and the National Comprehensive Cancer Network 1, 3
Each unit of packed red blood cells typically increases hemoglobin by approximately 1 g/dL, according to the National Comprehensive Cancer Network and the American Association for the Study of Liver Diseases 3, 4

Administer 2-3 units of packed red blood cells to increase hemoglobin from 6 g/dL to the target range of 7-9 g/dL, as recommended by the American Association for the Study of Liver Diseases 1, 4
Monitor vital signs and symptoms during transfusion to detect any transfusion reactions, as stated by the National Comprehensive Cancer Network and the Society of Critical Care Medicine 2, 3
Reassess hemoglobin levels after transfusion to confirm adequate response, according to the American Association for the Study of Liver Diseases and the National Comprehensive Cancer Network 1, 3

After initial stabilization with blood transfusion, investigate and treat the underlying cause of anemia, such as hemolysis, bone marrow suppression, or nutritional deficiencies, as recommended by the European Crohn’s and Colitis Organisation and the American Association for the Study of Liver Diseases 3, 4, 5
Following transfusion, intravenous iron supplementation should be considered, especially if iron deficiency is identified, according to the American Association for the Study of Liver Diseases and the European Crohn’s and Colitis Organisation 1, 5

In patients with cardiovascular disease, older age, or hemodynamic instability, maintaining higher hemoglobin levels (>8 g/dL) may be warranted, as stated by the Society of Critical Care Medicine and the American Association for the Study of Liver Diseases 2, 4
For patients with traumatic brain injury, a higher transfusion threshold may be considered, although evidence suggests they should be managed with the same threshold as other critically ill patients, according to the Society of Critical Care Medicine 2
If methemoglobinemia is suspected as a cause, specific treatments including methylene blue may be indicated, as recommended by the American Society of Hematology 6

After acute management, erythropoiesis-stimulating agents may be considered for patients with anemia of chronic disease who have inadequate response to iron therapy, as stated by the American Society of Hematology and the European Crohn’s and Colitis Organisation 5, 7
For patients with myelodysplastic syndromes or chronic myelomonocytic leukemia with severe anemia, erythropoietic stimulating agents should be considered, according to the European Hematology Association 8, 9

Regular monitoring of hemoglobin levels is essential until stable improvement is achieved, as recommended by the European Crohn’s and Colitis Organisation and the National Comprehensive Cancer Network 3, 5
Follow-up investigations should include assessment of reticulocyte count, iron studies, vitamin B12 and folate levels, according to the European Crohn’s and Colitis Organisation and the National Comprehensive Cancer Network 3, 5
Bone marrow examination may be necessary if primary bone marrow disorder is suspected, as stated by the European Hematology Association 8, 9